

DESCRIPTION

Source *E. coli*-derived
Thr23-Ser170, with an N-terminal Met and 6-His tag
Accession # Q9HCT0

N-terminal Sequence Analysis Met

Predicted Molecular Mass 18 kDa

SPECIFICATIONS

Activity Measured in a cell proliferation assay using 4MBr-5 rhesus monkey epithelial cells. Rubin, J.S. *et al.* (1989) Proc. Natl. Acad. Sci. USA **86**:802.
The ED₅₀ for this effect is 50-300 ng/mL.

Endotoxin Level <0.01 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 µg per lane.

Formulation Lyophilized from a 0.2 µm filtered solution in MES, Na₂SO₄, EDTA, Sucrose and DTT. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 100 µg/mL in sterile PBS.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Fibroblast growth factor-22 (FGF-22) is a 23 kDa, non-glycosylated member of the FGF-7 subfamily, from the FGF family of heparin-binding growth factors (1-3). The human FGF-22 precursor is 170 amino acids (aa) in length, and contains a 22 aa signal sequence with a 148 aa mature region (4-6). The mature region shows a centrally-placed, 120 aa β-trefoil region (aa 43-168) that is characteristic of all FGF family members. Human FGF-22 potentially has one alternate splice form. This isoform is 129 aa in length, and shows a 31 aa substitution for the first N-terminal 72 aa of the standard, or long, form (7). There is no information related to its possible function. Mature human FGF-22 is 86% aa identical to mouse FGF-22, with the mouse molecule showing a 9 aa deletion at the N-terminus (5). FGF-22 is synthesized by at least three cell types; keratinocytes, neurons, and skeletal muscle myotubes (4, 8, 9). In neurons and myotubes, FGF-22 is presumed to function as an organizer of the presynaptic apparatus. Expressed by postsynaptic (or target) cells, FGF-22 is believed to bind to FGF R2b on the surface of innervating processes, resulting in synaptic vesicle clustering, organization, and neurite branching (8, 10). Although FGF-22 is assumed to be secreted, little can be found in expressing cell culture media. Presumably, it is bound to 34 kDa FGF-BP1, which is a molecule described as typically associated with cell membrane proteoglycans (6, 11). Thus, following secretion, FGF-22 could quickly be immobilized by FGF-BP1, only to be released at a later time, or aided by FGF-BP1 in its interaction with FGF R2b (6, 10, 11).

References:

1. Itoh, N. and D.M. Ornitz (2004) Trends Genet. **20**:563.
2. Ornitz, D.M. and N. Itoh (2001) Genome Biol. **2**:3005.1 Epub 2001 Mar 9.
3. Nishimura, T. *et al.* (2000) Biochim. Biophys. Acta **1492**:203.
4. Beyer, T.A. *et al.* (2003) Exp. Cell Res. **287**:228.
5. Nakatake, Y. *et al.* (2001) Biochim. Biophys. Acta **1517**:460.
6. Beer, H-D. *et al.* (2005) Oncogene **24**:5269.
7. GenBank Accession #: EAW61176.
8. Fox, M.A. and H. Umemori (2006) J. Neurochem. **97**:1215.
9. Umemori, H. *et al.* (2004) Cell **118**:257.
10. Zhang, X. *et al.* (2006) J. Biol. Chem. **281**:15694
11. Xie, B. *et al.* (2006) J. Biol. Chem. **281**:1137.